Search
Patiromer
go.drugbank.com/drugs/DB09263ApprovedInvestigationalPatiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. … The chemical name for patiromer sorbitex calcium is cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene, combination with D-glucitol.
Categories: Compounds used in a research, industrial, or household settingRemestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnIt is estimated that the patients with the most severe forms of refractory aGvHD that do not respond to steroid therapy have expected one-year survival rates of only 5% to 30% [L11022]. … It was approved for use in Canada in May 2012 as Prochymal for the management of refractory acute Graft versus Host Disease (aGvHD) in children who are unresponsive to systemic steroid therapies, with
Influenza B virus B/Washington/02/2019 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB15702ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Fluarix Tetra Injektionssuspension in einer FertigspritzeBelantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawnIn the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program. … US marketing authorization in November 2022.
Valoctocogene roxaparvovec
go.drugbank.com/drugs/DB15561ApprovedInvestigationalWithdrawn[L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding. … [L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for the treatment of severe hemophilia A. It is not approved for use in the United States.
Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14389ApprovedInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: FluVaccinol Subunit Tetra Injektionssuspension in einer FertigspritzeValdecoxib
go.drugbank.com/drugs/DB00580ApprovedWithdrawnValdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Mephentermine
go.drugbank.com/drugs/DB01365ApprovedWithdrawn(From Martindale, The Extra Pharmacopoeia, 30th ed, p1248) … A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia.
Cocamidopropyl betaine
go.drugbank.com/drugs/DB11350ApprovedIt is a zwitterionic ammonium compound and fatty acid amide that contains a long hydrocarbon chain and a polar group at each end. … Cocamidopropyl betaine is used as a foam booster in shampoos, emulsifying agent, thickener, antistatic agent and rarely an antiseptic agent.
Categories: Compounds used in a research, industrial, or household settingInfluenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14404ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: FluVaccinol Subunit Tetra Injektionssuspension in einer Fertigspritze